A knot in a human umbilical cord. Relatively new FDA policies have impacted perinatal cell therapy biotech companies selling umbilical cord, amniotic, and placental products, which are now generally considered drug products requiring premarket approval. Creative Commons image: Scott Granneman.
https://ipscell.com/2022/05/end-of-fda-grace-period-impacted-perinatal-cell-therapy-biotechs/?utm_source=rss&utm_medium=rss&utm_campaign=end-of-fda-grace-period-impacted-perinatal-cell-therapy-biotechs